02/09/2022 (Agence Europe) – On Thursday 1 September, the European Commission granted conditional marketing authorisation for two SARS-CoV 2 vaccines adapted to the original virus and the BA.1 sub-variant.
These were a vaccine developed by PfizerBioNTech and another one developed by Moderna (see EUROPE B13012A23), both of which had been recommended a few hours earlier by the European Medicines Agency. Commissioner for Health Stella Kyriakides pointed out that the PfizerBioNTech and...